Adequacy of anticoagulant prevention inpatients with atrial fibrillation

被引:2
|
作者
García-García, J [1 ]
Calleja-Puerta, S [1 ]
de la Vega-Cerezales, V [1 ]
Benavente-Fernández, L [1 ]
Rodríguez-Rodríguez, S [1 ]
Hernández-Lahoz, C [1 ]
机构
[1] Univ Oviedo, Hosp Cent Asturias, Serv Neurol 2, E-33006 Oviedo, Asturias, Spain
关键词
atrial fibrillation; cardioembolic stroke; oral anticoagulants; prognosis; prophylaxis; stroke;
D O I
10.33588/rn.4107.2005231
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Although there is a consensus about the use of oral anticoagulants (OAC) to prevent stroke in patients with atrial fibrillation this treatment is underused in actual practice. Our aim was to determine the proportion of patients with previously known atrial fibrillation who were receiving OAC before stroke onset and their characteristics. Patients and methods. We recruited 50 patients who were admitted with acute stroke and previously known atrial fibrillation over a period of one year. Patients were classified according to the type of antithrombotic treatment they were on. The clinical picture was evaluated by the NIHSS. Functional prognosis was estimated by modifled-Rankin score at discharge. Results. Of 50 patients, 16 (32%) were receiving OAC before stroke. Four variables were associated with prescription of OAC: treatment with digoxin, previous ischemic stroke or transient ischemic accident, congestive heart failure and the type of AF (chronic vs paroxysmal). Age and medical history of arterial hypertension, diabetes mellitus or ischemic cardiopathy did not influence the prescription. According to the NIHSS and modifled-Rankin scales patients on OAC showed less serious strokes and presented a better functional situation at discharge than those who were not on that treatment. Conclusions. This study highlights the need to improve medical education about OAC in patients with atrial fibrillation because only 32% of patients received OAC before stroke although 90% of them should receive it according to current guidelines. Our results suggest that OAC treatment not only prevents stroke but may also contribute to the development of less serious strokes with a better functional prognosis.
引用
收藏
页码:399 / 403
页数:5
相关论文
共 50 条
  • [1] Which anticoagulant for stroke prevention in atrial fibrillation?
    Ball, Jocasta
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 359
  • [2] Selecting the right anticoagulant for stroke prevention in atrial fibrillation
    Kundnani, N. R.
    Rosca, C., I
    Sharma, A.
    Tudor, A.
    Rosca, M. S.
    Nisulescu, D. D.
    Branea, H. S.
    Mocanu, V
    Crisan, D. C.
    Buzas, D. R.
    Morariu, S.
    Lighezan, D. F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (13) : 4499 - 4505
  • [3] Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
    Turpie, Alexander G. G.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 197 - 205
  • [4] ATRIAL FIBRILLATION A promising new anticoagulant for stroke prevention
    Spinler, Sarah A.
    NATURE REVIEWS CARDIOLOGY, 2010, 7 (01) : 10 - 11
  • [5] Effects of Oral Anticoagulant Therapy in Medical Inpatients ≥65 Years With Atrial Fibrillation
    Bo, Mario
    Sciarrillo, Irene
    Puma, Federica Li
    Martini, Marco Badinella
    Falcone, Yolanda
    Iacovino, Marina
    Grisoglio, Enrica
    Menditto, Elena
    Fonte, Gianfranco
    Brunetti, Enrico
    Maggiani, Guido
    Isaia, Giovanni Carlo
    Gaita, Fiorenzo
    AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (04): : 590 - 595
  • [6] Anticoagulant Use for Prevention of Stroke in a Commercial Population with Atrial Fibrillation
    Patel, Aarti A.
    Lennert, Barb
    Macomson, Brian
    Nelson, Winnie W.
    Owens, Gary M.
    Mody, Samir H.
    Schein, Jeff
    AMERICAN HEALTH AND DRUG BENEFITS, 2012, 5 (05): : 291 - 297
  • [7] Prevention of stroke in patients with atrial fibrillation Anticoagulant and antiplatelet options
    Varughese, Christopher J.
    Halperin, Jonathan L.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2012, 35 (01) : 19 - 27
  • [8] What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
    Goldhaber, Samuel Z.
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) : 397 - 398
  • [9] Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation? The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation
    Lip, Gregory Y. H.
    Rushton-Smith, Sophie K.
    Goldhaber, Samuel Z.
    Fitzmaurice, David A.
    Mantovani, Lorenzo G.
    Goto, Shinya
    Haas, Sylvia
    Bassand, Jean-Pierre
    Camm, Alan John
    Ambrosio, Giuseppe
    Jansky, Petr
    Al Mahmeed, Wael
    Oh, Seil
    van Eickels, Martin
    Raatikainen, Pekka
    Steffel, Jan
    Oto, Ali
    Kayani, Gloria
    Accetta, Gabriele
    Kakkar, Ajay K.
    Lucas Luciardi, Hector
    Gibbs, Harry
    Brodmann, Marianne
    Cools, Frank
    Pereira Barretto, Antonio Carlos
    Connolly, Stuart J.
    Spyropoulos, Alex
    Eikelboom, John
    Corbalan, Ramon
    Hu, Dayi
    Nielsen, Jorn Dalsgaard
    Ragy, Hany
    Le Heuzey, Jean-Yves
    Darius, Harald
    Keltai, Matyas
    Kakkar, Sanjay
    Sawhney, Jitendra Pal Singh
    Agnelli, Giancarlo
    Koretsune, Yukihiro
    Sanchez Diaz, Carlos Jerjes
    Ten Cate, Hugo
    Atar, Dan
    Stepinska, Janina
    Panchenko, Elizaveta
    Lim, Toon Wei
    Jacobson, Barry
    Vinolas, Xavier
    Rosenqvist, Marten
    Angchaisuksiri, Pantep
    Parkhomenko, Alex
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2015, 8 (02): : S12 - S20
  • [10] QUALITATIVE STUDY ON INFLUENCES ON ANTICOAGULANT PRESCRIBING FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Jarrar, Rawand
    HEART, 2022, 108 : A58 - A59